Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Fuereder

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
ESMO Open|October 14, 2020
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing fieldMaximilian Marhold, Thais Topakian, Hermine Agis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyMakoto Tahara, Richard Greil, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.
The Journal of Infectious Diseases|December 31, 2009
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1Volker Wacheck, Andrej Egorov, Franz Groiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Nature Medicine|August 8, 2022
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialRupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, et al.
Nature Medicine|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trialMatthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
ESMO Open|October 14, 2020
Thirteen-year analyses of medical oncology outpatient day clinic data: a changing fieldMaximilian Marhold, Thais Topakian, Hermine Agis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyMakoto Tahara, Richard Greil, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.
The Journal of Infectious Diseases|December 31, 2009
A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1Volker Wacheck, Andrej Egorov, Franz Groiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Nature Medicine|August 8, 2022
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trialRupert Bartsch, Anna Sophie Berghoff, Julia Furtner, et al.
Oral Oncology|April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Danny Rischin, Kevin J Harrington, Richard Greil, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialRupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, et al.
Nature Medicine|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trialMatthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Pageof 8